Credit: NIAID and Colorado State University WHAT: A randomized, placebo-controlled Phase 1 clinical trial of two monoclonal antibodies (mAbs) directed against the coronavirus that causes Middle...
Analysis shows certain racial/ethnic groups and older people aren’t being adequately represented and trial reporting guidelines aren’t being followed Credit: Photo by Robert Hood / Fred...
With the vaccines now being administered at sites around the US, it is important to address misinformation surrounding the effort.
GlaxoSmithKline is expanding a coronavirus antibody collaboration with US biotech Vir, to include potential therapies for flu and The post GSK expands coronavirus antibody tie-up to...
Editorial emphasizes need for global response Credit: NIAID WHAT: The rise of several significant variants of SARS-CoV-2, the virus that causes COVID-19, has attracted the attention...
The pandemic winter will take longer than we thought. The longer we struggle with the coronavirus, the brighter gold could shine. A long, long time ago,...
The U.S. Food and Drug Administration granted Emergency Use Authorization (EUA) to a combination of Eli Lilly and AbCellera’s monoclonal antibody bamlanivimab and the Lilly antibody etesevimab...
Less than one week after posting a positive first-look at Phase III vaccine data, Maryland-based Novavax began the rolling review process for authorization of NVX-CoV2373 in...
GlaxoSmithKline is partnering with Germany’s CureVac to manufacture 100 million doses of that company’s mRNA Covid-19 vaccine CVnCoV, and collaborating to develop a next-generation multi-valent Covid-19 vaccine aimed...
Immuneering uses bioinformatically tuned target identification and hit finding platforms to generate drug candidates that can tamp down aberrant signalling. The post Disease Cancelling Technology Emulates...
Where conventional mass spec struggles with sequencing and the recognition of isoforms and post-translational modifications, new technologies may shine. The post Proteomics Begins to Emerge from...
Stirred to action by the COVID-19 pandemic, vaccine stalwarts mobilize new formats, accelerate development, and scale up manufacturing. The post The Sleeping Giants of Vaccine Production...
Credit: Helmholtz Zentrum München Researchers have discovered a novel and druggable insulin inhibitory receptor, named inceptor. The latest study from Helmholtz Zentrum Muenchen, the Technical University...
Neutralising antibodies aren't the only game in town.
Eli Lilly said new data showed that treatment with 2 of its antibody therapies lowered COVID-19-related hospitalizations & deaths in high-risk patients by 70%.
Vir Biotechnology, Eli Lilly and GlaxoSmithKline struck a three-way collaborative deal to evaluate Vir's investigational monoclonal antibody VIR-7831 in combination with Lilly’s bamlanivimab in low-risk patients with mild...
Phase 3 Trial Showed Eli Lilly’s bamlanivimab significantly reduced Covid-19 risk for nursing home residents
The new Covid-19 variant identified in South Africa can evade the antibodies that attack it in treatments using blood plasma from previously recovered patients, and may...
Measuring mitochondrial DNA could predict who will need ICU care, intubation Credit: WANDY BEATTY One of the most vexing aspects of the COVID-19 pandemic is doctors’...
While pharma has raced to develop COVID-19 vaccines, US-based company NeuroRx is taking a different approach to treating The post A new approach to COVID-19 treatment...
In this second ‘Nine for 2021‘ article, IQVIA’s Sarah Rickwood looks at four issues which will directly impact The post Nine for 2021: Addressing the pandemic...
In this eBook, sponsored by Origene, you will read about the fascinatingways bioengineering has changed how antibodymolecules are applied to research and the clinicalworld. Despite all...
COVID-19 has compressed bioprocessing timelines, leaving no room for uncertainty in the characterization of raw materials and contaminants. The post Bioprocessing in a Post-COVID-19 World appeared...
The companies created a combined antibody discovery and development platform for Charles River Labs clients that integrates Distributed Bio’s libraries and optimization technologies with Charles River’s...
'Mutant' Coronavirus: Six Experts Answer Your Questions Authored by Ethen Kim Lieser via 19fortyfive.com, Even as nations around the world are ramping up their respective vaccine...
The additional challenges to launching new drugs that emerged since COVID-19 upended the biopharma industry, and life as we knew it, will continue into 2021. Yet...
Credit: NIAID Cologne, Marburg, Braunschweig and Ingelheim, Germany, 18 December 2020 – Cologne University Hospital (UKK), University of Marburg (UMR), the German Center for Infection Research...
U.S. hospitals have been slow to embrace Covid-19 antibody drugs from Eli Lilly and Co. and Regeneron Pharmaceuticals Inc. that were authorized to reduce the risk...
Synthetic DNA-encoded monoclonal antibodies make the recipient’s body the production plant Credit: The Wistar Institute PHILADELPHIA — (Dec. 15, 2020) — A team of scientists from...
President-Elect Joe Biden announced this week that Rochelle Walensky, MD, MPH, chief of the division of infectious diseases at Massachusetts General Hospital, will replace Robert Redfield,...